China's BravoVax In-Licenses Rotavirus Vaccine For Infants

BravoVax of China in-licensed a rotavirus vaccine (RRV-TV) that can be administered to newborns, unlike competing vaccines, which are approved only for infants over the age of two months. The vaccine was developed by the International Medica Foundation of the US. BravoVax, a joint venture between Shanghai BravoBio and Humanwell Group of China, owns global rights to the vaccine except for the US, Europe and Japan. Financial details of the transaction were not disclosed.

Help employers find you! Check out all the jobs and post your resume.